Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

NCT01714661 | Completed Phase 3

• 2 other identifiers: EVP-6124-0152012-003208-10
• Study Type: interventional
• Target: 753
• Locations: 13 countries
• Sites: 94

Brief Summary

The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.

Conditions

Schizophrenia; Impaired Cognition

Keywords

Schizophrenia; Cognition; Cognition Impairment; Alpha-7 nAChR

Outcome Measures

Primary Outcomes (3)

• Change from Baseline in the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) to Day 182

  Baseline to Day 182 or Early Termination

• Change from Baseline in the Schizophrenia Cognition Rating Scale (SCoRs) to Day 182

  Baseline to Day 182 or Early Terminiation

• Safety and Tolerability of EVP-6124 or Placebo in Subjects with Schizophrenia

  All adverse experiences spontaneously reported by subject and/or observed by investigator and repeated clinical evaluation of physical examinations, vital signs, 12-lead ECG (electrocardiogram), ambulatory ECG, and laboratory tests (hematology/blood/chemistry/urinalysis)

  Screening (Day -42 to Day -15) to Day 182 or Early Terminiation

Secondary Outcomes (4)

• Change from Baseline in the Positive and Negative Symptom Scale (PANSS) to Day 182

  Baseline to Day 182 or Early Termination

• Change from Baseline in the Clinical Global Impression-Severity (CGI-S) to Day 182

  Baseline to Day 182 or Early Termination

• Change from Baseline in the Clinical Global Impression Change Scale (CGI-C) to Day 182

  Baseline to Day 182 or Early Termination

• Change from Baseline in the EuroQOL-5D (EQ-5D) to Day 182

  Baseline to Day 182 or Early Termination

Study Arms (3)

EVP-6124, low dose

EXPERIMENTAL

low dose, Tablet, Once Daily, Day 1 through Day 182

Drug: EVP-6124

EVP-6124, high dose

EXPERIMENTAL

high dose, Tablet, Once Daily, Day 1 through Day 182

Drug: EVP-6124

EVP-6124, Placebo

PLACEBO COMPARATOR

Placebo, Tablet, Once Daily, Day -14 through Day 182

Drug: Placebo

Interventions

EVP-6124 DRUG

Arms 1, 2

EVP-6124, high dose; EVP-6124, low dose

Placebo DRUG

Arm 3

EVP-6124, Placebo

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Age 18 to 50 years of age, inclusive
• Signed informed consent, indicating that the subject understands the purpose of and procedures required for the study, before the initiation of any study specific procedures. Subjects who are unable to provide informed consent will not be included in the study.
• Resides in a stable living situation, according to the investigator's judgment, and must have an identified informant who should be consistent throughout the study. If possible, the informant should accompany the subject or be available for in person ratings at the screening, baseline (Day 1), and final study visits. In person informant ratings on all relevant study visits are preferred whenever possible. However, if the informant is not available for in person ratings, telephone interview is acceptable. The informant must be available for a telephone interview throughout the study at all visits. As long as both the informant visit and subject visit are within the study visit windows, it is not necessary that they occur on the same day. The informant must interact with the subject at least 2 times a week.
• Diagnosis of Schizophrenia of at least 3 years duration. This diagnosis can be established utilizing the SCID-I, direct clinical assessments, family, informants, and confirmation of diagnosis from clinical sources. These may include medical records, confirmation of diagnosis by treating clinician through telephone contact, or written confirmation from treating clinic. If the listed sources are not available, other sources of diagnostic confirmation may also be acceptable after discussion with the medical monitor.
• Treated with atypical antipsychotic drug (in any approved dosage form) other than Clozapine at a stable dose for at least 8 weeks prior to screening and be clinically stable; the subject must remain clinically stable (in the opinion of the principal investigator) through randomization. The use of up to 2 atypical antipsychotic drugs is permitted, as long as in the opinion of the investigator, the second medication is not required to control treatment-resistant or intractable psychotic symptoms. No subject will be washed off antipsychotic therapy to become eligible for this study.
• Schizophrenia clinical symptom burden severity defined by the following: a Brief Psychiatric Rating Scale (BPRS) Conceptual Disorganization item score ≤ 4; and a BPRS Hallucinatory Behavior item score ≤ 5, or an Unusual Thought Content item score ≤ 5. Either Hallucinatory Behavior or Unusual Thought Content, but not both, may have a score of 6 (but not \> 6).
• Simpson-Angus Scale (SAS) total score ≤ 6
• Calgary Depression Scale for Schizophrenia (CDSS) total score ≤ 10
• General health status acceptable for participation in a 26-week clinical study
• Fertile, sexually active subjects (men and women) must use an effective method of contraception during the study
• Fluency (oral and written) in the language in which the standardized tests will be administered
• The ability to refrain from using any tobacco or other nicotine-containing products for at least 30 minutes before any cognitive testing

You may not qualify if:

• Hospitalization within 12 weeks before screening or during the screening period, or change of antipsychotic medication or dose within 8 weeks before screening or during the screening period.
• Participation in another therapeutic (medication administration) clinical study within the past 2 months.
• Psychiatric hospitalization or incarcerations due to breakthrough symptoms or acute exacerbations for a period of 3 months before screening. Subjects with a recent "social" hospitalization or incarceration may be entered into screening after consultation with the medical monitor
• Likelihood, in the opinion of the investigator, that either the subject or informant will be unable to complete a 26-week study
• Treatment with prohibited antipsychotic drug, and/or treatment with more than 2 permitted antipsychotic drugs. Treatment with a first-generation antipsychotic drug (typical antipsychotic) is prohibited unless it is administered at a low dose after discussion with the medical monitor
• Current treatment with any anticholinergic agent
• Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria met for alcohol abuse within the past 3 months or substance abuse (other than nicotine) within the last 6 months before screening
• Significant suicide risk as defined by 1) suicidal ideation as endorsed on items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within the past year; 2) suicidal behavior detected by the C-SSRS during the past 2 years, or 3) psychiatric interview and examination
• Stroke within 6 months before screening, history of brain tumor, subdural hematoma, or other clinically significant neurological condition, head trauma with loss of consciousness within 12 months before screening
• Monoamine oxidase inhibitor antidepressants or tricyclic medications used in antidepressant doses are excluded. Other antidepressant medications are allowed if the subject has been treated with a stable dose for at least 3 months before screening
• Immunosuppressants, mood stabilizers, chronic use of a sedative hypnotic drug, chronic intake of clinically significant doses of opioid containing analgesics or any current methadone treatment all in the judgment of the investigator may be permitted depending on the circumstance
• Use of Central Nervous System(CNS) stimulants
• Nicotine therapy (including patches), varenicline (Chantix), or similar therapeutic agent within the last six months before screening
• Use of a benzodiazepine medication is allowed if the subject has not had a change in medication or dose for at least 3 months. For subjects prescribed benzodiazepines, short-acting benzodiazepines are to be used whenever possible. Use of longer-acting benzodiazepines may be acceptable if prior authorization is obtained from the medical monitor. When possible, benzodiazepines should not be administered within 3 hours before cognitive testing. The use of more than one sedative-hypnotic medication is not allowed.

Sponsors & Collaborators

• FORUM Pharmaceuticals Inc: lead
• Syneos Health: collaborator
• NeuroCog Trials, Inc.: collaborator

Study Sites (94)

Unknown Facility

Tucson, Arizona, United States

Location

Unknown Facility

Anaheim, California, United States

Location

Unknown Facility

Bellflower, California, United States

Location

Unknown Facility

Costa Mesa, California, United States

Location

Unknown Facility

Culver City, California, United States

Location

Unknown Facility

Downey, California, United States

Location

Unknown Facility

Escondido, California, United States

Location

Unknown Facility

Los Angeles, California, United States

Location

Unknown Facility

Oceanside, California, United States

Location

Unknown Facility

Orange, California, United States

Location

Unknown Facility

San Diego, California, United States

Location

Unknown Facility

Torrance, California, United States

Location

Unknown Facility

Lauderhill, Florida, United States

Location

Unknown Facility

Miami, Florida, United States

Location

Unknown Facility

North Miami, Florida, United States

Location

Unknown Facility

Orange City, Florida, United States

Location

Unknown Facility

Atlanta, Georgia, United States

Location

Unknown Facility

Chicago, Illinois, United States

Location

Unknown Facility

Wichita, Kansas, United States

Location

Unknown Facility

Shreveport, Louisiana, United States

Location

Unknown Facility

Minneapolis, Minnesota, United States

Location

Unknown Facility

Flowood, Mississippi, United States

Location

Unknown Facility

Creve Coeur, Missouri, United States

Location

Unknown Facility

O'Fallon, Missouri, United States

Location

Unknown Facility

St Louis, Missouri, United States

Location

Unknown Facility

Omaha, Nebraska, United States

Location

Unknown Facility

Marlton, New Jersey, United States

Location

Unknown Facility

Albuquerque, New Mexico, United States

Location

Unknown Facility

Cedarhurst, New York, United States

Location

Unknown Facility

New York, New York, United States

Location

Unknown Facility

Charlotte, North Carolina, United States

Location

Unknown Facility

Durham, North Carolina, United States

Location

Unknown Facility

Cleveland, Ohio, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, United States

Location

Unknown Facility

Conshohocken, Pennsylvania, United States

Location

Unknown Facility

Norristown, Pennsylvania, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, United States

Location

Unknown Facility

Dallas, Texas, United States

Location

Unknown Facility

La Plata, Buenos Aires, Argentina

Location

Unknown Facility

Caba, Buenos Aires F.D., Argentina

Location

Unknown Facility

Córdoba, Córdoba Province, Argentina

Location

Unknown Facility

Mendoza, Mendoza Province, Argentina

Location

Unknown Facility

Melbourne, Australia

Location

Unknown Facility

Rio de Janeiro, Rio de Janeiro, Brazil

Location

Unknown Facility

Itapira, São Paulo, Brazil

Location

Unknown Facility

São Paulo, Brazil

Location

Unknown Facility

Calgary, Alberta, Canada

Location

Unknown Facility

Penticton, British Columbia, Canada

Location

Unknown Facility

Chatham, Ontario, Canada

Location

Unknown Facility

Kingston, Ontario, Canada

Location

Unknown Facility

Montreal, Quebec, Canada

Location

Unknown Facility

Achim, Germany

Location

Unknown Facility

Berlin, Germany

Location

Unknown Facility

Düsseldorf, Germany

Location

Unknown Facility

Freiburg im Breisgau, Germany

Location

Unknown Facility

Leipzig, Germany

Location

Unknown Facility

Mittweida, Germany

Location

Unknown Facility

München, Germany

Location

Unknown Facility

Regebsburg, Germany

Location

Unknown Facility

Regensburg, Germany

Location

Unknown Facility

Stralsund, Germany

Location

Unknown Facility

Wiesbaden, Germany

Location

Unknown Facility

México, D.F, Mexico

Location

Unknown Facility

Guadalajara, Jalisco, Mexico

Location

Unknown Facility

Monterrey, Neuvo Leon, Mexico

Location

Unknown Facility

Bialystok, Poland

Location

Unknown Facility

Gdansk, Poland

Location

Unknown Facility

Lodz, Poland

Location

Unknown Facility

Lublin, Poland

Location

Unknown Facility

Torun, Poland

Location

Unknown Facility

Tuszyn, Poland

Location

Unknown Facility

Warsaw, Poland

Location

Unknown Facility

Talagi, Arkhangelskaya oblast, Russia

Location

Unknown Facility

Moscow, Moscow, Russia

Location

Unknown Facility

Saint Petersburg, Sankt-Peterburg, Russia

Location

Unknown Facility

Stavropol, Russia

Location

Unknown Facility

Belgrade, Serbia

Location

Unknown Facility

Kragujevac, Serbia

Location

Unknown Facility

Niš, Serbia

Location

Unknown Facility

Novi Kneževac, Serbia

Location

Unknown Facility

Singapore, Singapore, Singapore

Location

Unknown Facility

Barcelona, Barcelona, Spain

Location

Unknown Facility

Mataró, Barcelona, Spain

Location

Unknown Facility

Salamanca, Castille and León, Spain

Location

Unknown Facility

Zamora, Castille and León, Spain

Location

Unknown Facility

Alcorcón, Madrid, Spain

Location

Unknown Facility

Coslada, Madrid, Spain

Location

Unknown Facility

Madrid, Madrid, Spain

Location

Unknown Facility

Vigo, Pontevedra, Spain

Location

Unknown Facility

Donetsk, Ukraine

Location

Unknown Facility

Ivano-Frankivsk, Ukraine

Location

Unknown Facility

Kharkiv, Ukraine

Location

Unknown Facility

Kyiv, Ukraine

Location

Unknown Facility

Luhansk, Ukraine

Location

MeSH Terms

Conditions

Schizophrenia; Cognition Disorders

Interventions

7-chloro-N-quinuclidin-3-yl-benzo(b)thiophene-2-carboxamide

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Neurocognitive Disorders

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 19, 2012
• First Posted: October 26, 2012
• Study Start: October 1, 2012
• Primary Completion: December 1, 2015
• Study Completion: December 1, 2015
• Last Updated: May 3, 2016

Record last verified: 2015-06

Locations

SG (1); ME (3); BR (3); UA (5); DE (11); ES (8); US (38); PL (7); AR (4); AU (1); CA (5); RU (4); SE (4)